Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Psychiatry. 1990 Jun;147(6):798-800.

Buspirone augmentation of fluoxetine in obsessive-compulsive disorder.

Author information

1
Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH.

Abstract

Eleven obsessive-compulsive patients underwent a prospective open-label trial of fluoxetine monotherapy followed by buspirone augmentation. The combination therapy was statistically superior to fluoxetine monotherapy. The results point to the importance of the 5-HT1a receptor in obsessive-compulsive disorder.

PMID:
2188516
DOI:
10.1176/ajp.147.6.798
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center